Agilent stock price target maintained at $150 by TD Cowen on strong growth

Published 28/08/2025, 14:56
Agilent stock price target maintained at $150 by TD Cowen on strong growth

Investing.com - TD Cowen has reiterated its Buy rating and $150.00 price target on Agilent (NYSE:A), currently trading at $122.27, following the company’s quarterly results that showed strong revenue growth despite margin pressure. According to InvestingPro data, analyst targets range from $120 to $165, with the company maintaining a GOOD financial health score.

The laboratory equipment maker, with a market capitalization of $34.7 billion, reported organic growth of 6.1% in its fiscal third quarter, significantly outpacing the consensus expectation of 3.6%, according to TD Cowen analyst Dan Brennan.

The firm noted that Agilent’s growth was "broad based" across its business segments, with the company forecasting continued strong performance through the fiscal fourth quarter and into the first quarter of fiscal 2026.

Despite the revenue beat, Agilent’s margins missed analyst expectations by approximately 150 basis points, which TD Cowen attributed to tariffs, foreign exchange impacts, and ongoing investments.

The research firm maintained its positive outlook on Agilent, citing expectations for "improving top line & margin expansion ahead" despite the current margin challenges.

In other recent news, Agilent Technologies reported its third-quarter earnings for 2025, meeting expectations with an earnings per share (EPS) of $1.37. The company’s revenue for the quarter exceeded forecasts, coming in at $1.74 billion against the anticipated $1.67 billion. This marks a significant development for Agilent as it demonstrates strong performance in its financial results. Additionally, Bernstein SocGen Group reiterated its Market Perform rating for Agilent, maintaining a price target of $125.00. Analyst Eve Burstein highlighted Agilent’s fifth consecutive quarter of sequential core revenue acceleration, indicating widespread improvement across its business segments. These recent developments reflect a positive trajectory for Agilent, with strong organic growth signaling continued market recovery.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.